BG-C0902 alone and with other therapies for people with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human Phase 1a/1b study tests BG-C0902, a fully human antibody that targets EGFR and MET and is linked to a topoisomerase 1 inhibitor via a cleavable linker, in patients with advanced solid tumors. Phase 1a includes dose escalation and safety expansion to identify a tolerable dose and characterize pharmacokinetics and pharmacodynamics, and Phase 1b comprises dose-expansion cohorts and combination arms. Primary assessments focus on safety, tolerability, PK/PD, and preliminary antitumor activity using RECIST v1.1. Participants must provide tumor tissue, have measurable disease, ECOG performance status ≤1, and be treated at participating US cancer centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors not amenable to therapy with curative intent or for whom treatment is not available or not tolerated.
* Participants must be able to provide archival tissue formalin-fixed paraffin-embedded (FFPE) block containing tumor tissue or approximately 10 to 15 freshly cut unstained FFPE slides) or recently obtained fresh tumor biopsy samples at screening.
* Participants must have ≥ 1 measurable lesion as assessed by RECIST v1.1.
* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1, as assessed ≤ 14 days before the first dose of study drug.
* Adequate bone marrow and organ function as indicated by the following laboratory values ≤ 14 days before the first dose of study drug
* Female participants of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 7 months after the last dose of study drug. They must also have a negative serum pregnancy test result ≤ 3 days before the first dose of study drug.
* Nonsterile male participants must be willing to use a highly effective method of birth control and refrain from sperm donation for the duration of the study and for ≥ 4 months after the last dose of study drug.

Exclusion Criteria:

* History of severe allergic reactions or hypersensitivity to BG-T187 or other monoclonal antibodies, or to the active ingredient and excipients of the study drug or camptothecins.
* For Phase 1a Part B Safety Expansion and Phase 1b only: Prior treatment with an EGFR-targeting ADC or mesenchymal-epithelial transition (MET)-targeting antibody-drug conjugate (ADC), or any ADC with topoisomerase I (TOPO1) inhibitor payload.
* Active leptomeningeal disease or uncontrolled, untreated brain metastasis. Participants with a history of treated and, at the time of screening, stable central nervous system (CNS) metastases are eligible, provided they meet all the following:

  1. Brain imaging at screening shows no evidence of interim progression, is clinically stable for ≥ 4 weeks, and has no evidence of new brain metastases
  2. Have measurable disease and/or evaluable disease outside CNS
  3. No ongoing requirement for corticosteroids as therapy for CNS disease; off corticosteroids ≥ 14 days before dosing with study drug; anticonvulsants at a stable dose are allowed
  4. No stereotactic radiation or whole-brain radiation ≤ 14 days before the first dose of study drug
* History of interstitial lung disease (ILD), or ≥ Grade 2 noninfectious pneumonitis ≤ 2 years before the first dose of the study drug, or has current ILD/noninfectious pneumonitis, or where suspected active ILD/noninfectious pneumonitis cannot be ruled out by imaging during screening.
* Participants with active or chronic corneal disorder, including but not limited to Sjögren's, Fuch's corneal dystrophy, history of corneal transplantation, corneal keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration, other active ocular conditions and any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it's running

• The University of Texas Md Anderson Cancer Center
  Houston, Texas, United States Recruiting
• Next Oncology
  San Antonio, Texas, United States Recruiting
• Next Oncology Virginia
  Fairfax, Virginia, United States Recruiting
• Blacktown Cancer and Haematology Centre
  Blacktown, New South Wales, Australia Recruiting
• Cancer Research South Australia
  Adelaide, South Australia, Australia Recruiting
• Monash Health
  Clayton, Victoria, Australia Recruiting

Study contacts

• Study coordinator: Study Director
• Email: clinicaltrials@beonemed.com
• Phone: 1.877.828.5568

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PEP08 for adults with advanced MTAP‑deleted solid tumors

  This trial will test whether PEP08, given alone or with another cancer drug, is safe and shows signs of benefit in adults with advanced or metastatic solid tumors that have MTAP deletion.

  Recruiting at 4 sites Phase 1 PharmaEngine · Wentworthville, New South Wales and 3 other locations · NCT06973863

• BA1203 in advanced solid tumors: safety and early signs of activity

  This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.

  Recruiting Phase 1 Shandong Boan Biotechnology Co., Ltd · Beijing · NCT07876609

• BL-M08D treatment in melanoma and other solid tumors

  A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07841925

• REC-7735 for PIK3CA-H1047R-mutant solid tumors

  This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.

  Recruiting at 3 sites Phase 1/2 Recursion Pharmaceuticals Inc. · Grand Rapids, Michigan and 2 other locations · NCT07819136

• Preferences of physicians and patients for cell therapies in advanced solid tumors

  This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.

  Recruiting Zhejiang University · Hangzhou, Zhejiang · NCT07813000

• SGT003 in people with advanced solid tumors

  This early-phase study tests SGT003 in adults with advanced solid tumors to see if it is safe and tolerable and to get a first look at how it behaves in the body and any early signs of benefit.

  Recruiting Phase 1/2 Beijing Sungen Biomedical Technology Co., Ltd · Beijing, Beijing Municipality · NCT07811037

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.